5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3′-bipyridine: A highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 15, 2004, Pages 3993-3996

  Roppe, Jeffrey R ^a   Wang, Bowei ^a   Huang, Dehua ^a   Tehrani, Lida ^a   Kamenecka, Theodore ^a   Schweiger, Edwin J ^a   Anderson, Jeffery J ^b   Brodkin, Jesse ^b   Jiang, Xiaohui ^a   Cramer, Merryl ^a   Chung, Janice ^a   Reyes Manalo, Grace ^a   Munoz, Benito ^a   Cosford, Nicholas D P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Merck Laboratories   (United States)

Author keywords

Metabotropic glutamate receptor; mGluR; mGluR5; MPEP; MTEP

Indexed keywords

5 [(2 METHYL 1,3 THIAZOL 4 YL)ETHYNYL] 2,3' BIPYRIDINE; GLUTAMATE RECEPTOR ANTAGONIST; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; NONHUMAN; RAT; RECEPTOR BINDING; STARTLE REFLEX; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; KINETICS; MODELS, MOLECULAR; PYRIDINES; RECEPTORS, METABOTROPIC GLUTAMATE; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 3042598793     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.05.037     Document Type: Article

References (21)

1. Ozawa S., Kamiya H., Tsuzuki K. Prog. Neurobiol. 54:1998;581-618. (Oxford)
2. Brauener-Osborne H., Egebjerg J., Nielsen E.O., Madsen U., Krogsgaard-Larsen P. J. Med. Chem. 43:2000;2609
3. Pin J.-P., Acher F. Curr. Drug Targets: CNS Neurol. Disord. 1:2002;297
4. Conn P.J., Pin J.-P. Annu. Rev. Pharmacol. Toxicol. 37:1997;205
5. Varney M.A., Gereau R.W.I. Curr. Drug Targets: CNS Neurol. Disord. 1:2002;283
6. Brodkin J., Busse C., Sukoff S.J., Varney M.A. Pharmacol. Biochem. Behav. 73:2002;359
7. Spooren W.P.J.M., Vassout A., Neijt H.C., Kuhn R., Gasparini F., et al. J. Pharmacol. Exp. Ther. 295:2000;1267
8. Spooren W.P.J.M., Schoeffter P., Gasparini F., Kuhn R., Gentsch C. Eur. J. Pharmacol. 435:2002;161
9. Tatarczynska E., Klodzinska A., Chojnacka-Wojcik E., Palucha A., Gasparini F., et al. Br. J. Pharmacol. 132:2001;1423
10. Klodzinska A., Tatarczynska E., Chojnacka-Wojcik E., Pilc A. Pol. J. Pharmacol. 52:2000;463
11. Schulz B., Fendt M., Gasparini F., Lingenhohl K., Kuhn R., et al. Neuropharmacology. 41:2001;1
12. Chiamulera C., Epping-Jordan M.P., Zocchi A., Marcon C., Cottiny C., et al. Nat. Neurosci. 4:2001;873
13. Huber K.M., Gallagher S.M., Warren S.T., Bear M.F. Proc. Nat. Acad. Sci. 99:2002;7746
14. Cosford N.D.P., Tehrani L., Roppe J., Schweiger E., Smith N.D., et al. J. Med. Chem. 46:2003;204
15. Varney M.A., Cosford N.D.P., Jachec C., Rao S.P., Sacaan A., et al. J. Pharmacol. Exp. Ther. 290:1999;170
16. Varney M.A., Suto C.M. Drug Discovery Today: HTS Suppl. 1:2000;20
17. Daggett L.P., Sacaan A.I., Akong M., Rao S.P., Hess S.D., et al. Neuropharmacology. 34:1995;871
18. Cosford N.D.P., Roppe J., Tehrani L., Seiders T.J., Schweiger E.J., et al. Bioorg. Med. Chem. Lett. 13:2003;351
19. Anderson J.J., Bradbury M.J., Giracello D.R., Chapman D.F., Holtz G., Roppe J., et al. Eur. J. Parmacol. 473:2003;35
20. Busse, C. S.; Brodkin, J.; Tattersall, D.; Anderson, J. J.; Warren, N. A.; Tehrani, L.; Bristow, L. J.; Varney, M. A.; Cosford, N. D. P. The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety, Neurophyschopharmacology, 2004, in press
21. Klodzinska, A.; Tatarczynska, E.; Chojnacka-Wojcik, E.; Nowak, G.; Cosford, N. D. P.; Pilc, A. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABAA signaling, Neuropharmacology, 2004, in press